Literature DB >> 18369576

Immunosuppressive properties of surfactant in alveolar macrophage NR8383.

J Kerecman1, S B Mustafa, M M Vasquez, P S Dixon, R Castro.   

Abstract

OBJECTIVE: To evaluate the anti-inflammatory effects of exogenous surfactants and surfactant phospholipid without surfactant proteins (SP-A and SP-D) on the lipopolysaccharide- (LPS) stimulated rat alveolar macrophage (AM) cell line NR8383.
METHODS: Exogenous surfactants (beractant, calfactant or colfosceril) and surfactant phospholipid (dipalmitoyl phosphatidylcholine, DPPC), standardized to phospholipid content of 25-1,000 microg/ml were incubated with LPS- (1 microg/ml) stimulated NR8383 AMs.
RESULTS: TNF-alpha and IL-1beta secretion and nitric oxide (NO) formation following LPS stimulation were inhibited by treatment with surfactants or DPPC. Furthermore, LPS-dependent NO production and iNOS protein levels were significantly suppressed in cells pretreated for one hour with beractant compared to beractant added simultaneously with or following LPS. Additionally, LPS-stimulated oxidative burst, measured by flow cytometry, was significantly decreased by beractant. Finally, beractant inhibited the translocation of NF-kappaB from cytoplasmic into nuclear extract in LPS-stimulated NR8383 AMs.
CONCLUSIONS: Exogenous surfactants and surfactant phospholipid inhibit secretion of proinflammatory cytokines and NO in NR8383 AMs. The inhibitory effects of beractant on oxygen radical and LPS-induced NO formation may result from unique mechanisms of decreasing cell signaling. The anti-inflammatory activity of surfactant products used in the treatment of neonatal respiratory distress syndrome (RDS) may depend upon the specific preparation or dose used.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18369576     DOI: 10.1007/s00011-007-7212-1

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  7 in total

1.  Effect of ozone exposure and infection on bronchoalveolar lavage: sex differences in response patterns.

Authors:  Anatoly N Mikerov; David S Phelps; Xiaozhuang Gan; Todd M Umstead; Rizwanul Haque; Guirong Wang; Joanna Floros
Journal:  Toxicol Lett       Date:  2014-04-21       Impact factor: 4.372

2.  Oxidized phospholipid, 1-palmitoyl-2-(9'-oxo-nonanoyl)-glycerophosphocholine (PON-GPC), produced in the lung due to cigarette smoking, impairs immune function in macrophages.

Authors:  Tomomi Kimura; Yoko Shibata; Keiko Yamauchi; Akira Igarashi; Sumito Inoue; Shuichi Abe; Kazuhiro Fujita; Yoichi Uosaki; Isao Kubota
Journal:  Lung       Date:  2011-10-11       Impact factor: 2.584

3.  Aberrant lung remodeling in a mouse model of surfactant dysregulation induced by modulation of the Abca3 gene.

Authors:  Michael F Beers; Lars Knudsen; Yaniv Tomer; Julian Maronn; Ming Zhao; Matthias Ochs; Surafel Mulugeta
Journal:  Ann Anat       Date:  2016-12-26       Impact factor: 2.698

4.  Surfactant blocks lipopolysaccharide signaling by inhibiting both NFκB and PARP activation in experimental ARDS.

Authors:  Neha Mittal; Sankar Nath Sanyal
Journal:  Mol Cell Biochem       Date:  2011-04-02       Impact factor: 3.396

5.  Effect of exogenous surfactant on Paediatric Bronchoalveolar lavage derived macrophages' cytokine secretion.

Authors:  Lyné van Rensburg; Johann M van Zyl; Johan Smith; Pierre Goussard
Journal:  BMC Pulm Med       Date:  2019-12-05       Impact factor: 3.317

6.  Early Immunomodulatory Effects of Different Natural Surfactant Preparations in Preterms With Respiratory Distress.

Authors:  Mehmet Yalaz; Sema Tanriverdi; Özgün Uygur; Özge Altun Köroğlu; Elif Azarsiz; Guzide Aksu; Nilgün Kültürsay
Journal:  Front Pediatr       Date:  2022-03-18       Impact factor: 3.418

7.  Effects of the New Generation Synthetic Reconstituted Surfactant CHF5633 on Pro- and Anti-Inflammatory Cytokine Expression in Native and LPS-Stimulated Adult CD14+ Monocytes.

Authors:  Kirsten Glaser; Markus Fehrholz; Tore Curstedt; Steffen Kunzmann; Christian P Speer
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.